Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

OXFENDAZOLE WITH IMPURITY D CRS (20 MG)

OXFENDAZOLE WITH IMPURITY D CRS (20 MG)

53716-50-0

DISCOVER
MOXONIDINE CRS (50 MG)

MOXONIDINE CRS (50 MG)

75438-57-2

DISCOVER
MESO-RICH EXAMETAZIME CRS (0.5 MG)

MESO-RICH EXAMETAZIME CRS (0.5 MG)

105613-48-7

DISCOVER
Demethylflumazenil - reference spectrum, Qty : n/a

Demethylflumazenil - reference spectrum, Qty : n/a

NA

DISCOVER
PHENYLMERCURIC ACETATE - REFERENCE SPECTRUM (N/A)

PHENYLMERCURIC ACETATE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
DIHYDRALAZINE FOR SYSTEM SUITABILITY CRS (15 MG)

DIHYDRALAZINE FOR SYSTEM SUITABILITY CRS (15 MG)

7327-87-9

DISCOVER
PAROXETINE IMPURITY A CRS (15MG)

PAROXETINE IMPURITY A CRS (15MG)

NA

DISCOVER
N,N-DIMETHYLACETAMIDE - REFERENCE SPECTRUM (N/A)

N,N-DIMETHYLACETAMIDE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
ALMAGATE CRS (50 MG)

ALMAGATE CRS (50 MG)

66827-12-1

DISCOVER
FLUSPIRILENE CRS (20 MG)

FLUSPIRILENE CRS (20 MG)

1841-19-6

DISCOVER
PERINDOPRIL IMPURITY A CRS (15 MG)

PERINDOPRIL IMPURITY A CRS (15 MG)

80875-98-5

DISCOVER
PERINDOPRIL TERT-BUTYLAMINE CRS (40 MG)

PERINDOPRIL TERT-BUTYLAMINE CRS (40 MG)

107133-36-8

DISCOVER